Biblio
Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2. Cell Rep. 2022;38(4):110253.
PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes. Br J Cancer. 2024.
. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia. Sci Transl Med. 2023;15(689):eabq8513.
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/mA/PFKP/LDHB axis. Mol Cell. 2021.
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020.